Immuno-Oncology | Specialty

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Dr. Chachoua Describes Clinical Trials Evaluating Immunotherapy in Lung Cancer

July 2nd 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Dr. Jurcic on the Next Steps for Radioimmunotherapy

June 30th 2014

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

June 25th 2014

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.

Why Chemotherapy Remains Vital in an Era of Targeted Agents and Immunotherapies

June 20th 2014

When Franco Muggia, MD, was a freshly minted oncologist 50 years ago, his new colleagues warned him not to waste much time learning about a drug like fluorouracil.

Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial

June 20th 2014

Edith A. Perez, MD, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Checkpoint Agents Are Shifting Paradigms Toward Immunotherapy

June 16th 2014

The concept of manipulating the immune system to treat cancer has experienced waxing and waning levels of enthusiasm over decades of clinical investigation.

Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

June 10th 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.

Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC

June 6th 2014

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.

Dr. Wolchok on Ipilimumab After Complete Resection of Stage III Melanoma

June 5th 2014

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, Giant of Cancer Care, discusses the initial efficacy and safety results from the EORTC 18071 phase III trial, which looked at ipilimumab versus placebo after complete resection of stage III melanoma.

Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma

June 3rd 2014

Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma

June 2nd 2014

The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.

Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma

June 2nd 2014

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

Dr. Fong Discusses Intratumoral Electroporation of Plasmid IL-12 in Melanoma

June 2nd 2014

Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Investigational Immunotherapy Granted First Breakthrough Therapy Designation in Bladder Cancer

June 1st 2014

MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.

Dr. Pavlick on a Phase II Trial of Cyclophosphamide and Ipilimumab in Melanoma

May 28th 2014

Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.

Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

May 27th 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Nivolumab, Elotuzumab Receive Breakthrough Therapy Designations for Types of Blood Cancer

May 19th 2014

Over the course of only a few days, two drugs that will be commercialized by Bristol-Myers Squibb (BMS), nivolumab and elotuzumab, have each been granted breakthrough therapy designations by the FDA for the treatment of two different types of blood cancers.

x